Kindred Bio

KIN NASDAQ
7.73
-0.22
-2.77%
After Hours: 7.73 0 0.00% 16:23 06/14 EDT
Open
7.95
Prev Close
7.95
High
8.06
Low
7.70
Volume
59.49K
Avg Vol (3M)
179.32K
52 Week High
15.75
52 Week Low
7.56
% Turnover
0.15%
Market Cap
301.51M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Kindred Bio KIN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
MORE >

Recently

Name
Price
%Change